Buckhead Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Buckhead Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,980	Closed	-$241K	–	160
2018 Q1	$241K	Buy	+11,980	New	+$203K	0.05%	164
2017 Q2	–	Sell	-15,555	Closed	-$351K	–	173
2017 Q1	$351K	Sell	15,555 -790	-5%	-$18.9K	0.06%	140
2016 Q4	$569K	Sell	16,345 -2,200	-12%	-$65.7K	0.11%	120
2016 Q3	$455K	Sell	18,545 -10,625	-36%	-$266K	0.09%	142
2016 Q2	$698K	Sell	29,170 -1,693	-5%	-$38.8K	0.13%	124
2016 Q1	$722K	Buy	30,863 +13,781	+81%	+$327K	0.13%	133
2015 Q4	$516K	Buy	+17,082	New	+$552K	0.1%	157

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Buckhead Capital Management's AMAG Position: Q2 2018 in Review

Buckhead Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q2 2018, closing a stake of 11,980 shares — an estimated $241K sold.

Buckhead Capital Management first reported a position in AMAG in Q4 2015 and held it in 7 quarters. The position peaked at $722K in Q1 2016. 173 funds tracked by Wall St. Rank hold AMAG as of Q2 2018.

Buckhead Capital Management reported no remaining AMAG Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Buckhead Capital Management sold 11,980 AMAG Pharmaceuticals shares in Q2 2018, an estimated $241K.
Buckhead Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 7 quarters.
Buckhead Capital Management's AMAG Pharmaceuticals position peaked at $722K in Q1 2016.
173 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2018.

Based on Buckhead Capital Management's 13F filing for Q2 2018, filed 2 Aug 2018.